Beam Therapeutics Inc. — Q3 2022 Form 10-Q Summary
Business context and reporting period
Beam is an early-stage biotechnology company developing precision genetic medicines using base editing and multiple delivery modalities, including electroporation, lipid nanoparticles and AAV vectors. The filing covers the three and nine months ended September 30, 2022. The company has not generated product-sales revenue and remains focused on preclinical and early clinical development.
Key financial metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| License and collaboration revenue | $15.8 million | $40.9 million |
| Research and development expense | $85.3 million | $225.3 million |
| General and administrative expense | $21.8 million | $65.1 million |
| Loss from operations | $(91.3) million | $(249.5) million |
| Net loss | $(109.6) million | $(250.7) million |
| Net loss per share | $(1.56) | $(3.59) |
| Net cash provided by operating activities | Not separately provided for the quarter | $91.7 million |
- Revenue increased substantially because of recognition under the Pfizer and Apellis collaborations.
- Cash and cash equivalents were $156.5 million; marketable securities were $938.0 million; and restricted cash was $12.8 million at September 30, 2022.
- Cash, cash equivalents and marketable securities totaled approximately $1.1 billion, which management expects to fund operations for at least 12 months from issuance of the financial statements.
- Total assets were $1.35 billion and stockholders’ equity was $714.5 million.
- Current liabilities were $238.9 million. Equipment financing liabilities totaled $3.6 million, while operating lease liabilities totaled $174.9 million. The filing does not identify significant conventional borrowing.
- Accumulated deficit was $1.019 billion.
- Investing cash use was $574.8 million, primarily net purchases of marketable securities and $40.7 million of property and equipment. Financing cash inflow was $79.6 million, primarily from equity offerings.
Material changes versus the prior comparable period
- Third-quarter revenue rose from $0.8 million to $15.8 million, while nine-month revenue rose from $0.8 million to $40.9 million.
- Third-quarter operating expenses increased 52% to $107.1 million, driven by higher personnel, facilities, stock-based compensation, laboratory supplies and outsourced services.
- Nine-month research and development expense decreased 22% from $290.3 million to $225.3 million, primarily because 2021 included a $155.0 million write-off of Guide acquisition in-process research and development. Excluding that unusual item, 2022 development spending increased materially.
- Nine-month net loss improved from $305.9 million to $250.7 million, but the third-quarter net loss widened from $28.1 million to $109.6 million.
- Operating cash flow improved to $91.7 million from $(68.1) million, largely because Beam collected the $300.0 million Pfizer collaboration receivable in January 2022.
- Beam recognized a $25.5 million loss related to its equity-method investment in Orbital Therapeutics, reducing the investment’s carrying value to zero.
- Beam issued additional shares under its ATM program, bringing total gross proceeds from the amended program to $289.3 million as of September 30, 2022. Shares outstanding increased to approximately 70.5 million from 68.4 million at December 31, 2021.
Guidance, outlook, commentary and risks
- Management expects continued operating losses and negative operating cash flows for the foreseeable future and anticipates needing additional financing through equity, debt, collaborations or licensing arrangements.
- Beam expected to enroll the first patient in the BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease by the end of 2022. BEAM-101’s IND had been cleared and multiple U.S. trial sites were recruiting.
- Beam decided not to submit an IND for BEAM-102 in 2022 and planned to optimize the program for later development waves.
- The FDA placed the BEAM-201 IND on clinical hold in July 2022 and requested additional genomic-rearrangement controls, off-target analyses, cytokine-independent growth assay controls and an updated investigator brochure. The company stated that it submitted a response in November 2022.
- Beam expected its 100,000-square-foot North Carolina cGMP manufacturing facility to become operational in the first quarter of 2023. The facility carries substantial future lease commitments, and total undiscounted operating lease payments were $265.2 million at September 30, 2022.
- In September 2022, Beam entered into a collaboration with Orbital Therapeutics and received a 31.5% fully diluted equity interest. The transaction generated $25.5 million of expense and $25.5 million of deferred revenue; no Orbital revenue had been recognized by September 30.
- Beam accrued $3.4 million related to allegations by a research institution involving breach of confidentiality, trade-secret misappropriation and related claims concerning BEAM-102 and BEAM-302. The settlement proposal was rejected, no complaint had been filed, and the ultimate loss could materially exceed the accrued amount.
- Remaining success-payment liabilities to Harvard and the Broad Institute totaled $21.3 million at September 30, 2022, and each institution could receive up to an additional $90.0 million under the applicable agreements.
- Material risks include clinical and regulatory failure, manufacturing execution, dependence on collaboration partners, the need for additional capital, intellectual-property priority and infringement disputes, potential trade-secret claims, employee retention, supply-chain disruption and COVID-19 impacts.
Most important facts for investors to verify
- Whether the BEACON trial enrolled its first patient by year-end 2022 and the timing of subsequent clinical data.
- Whether the FDA lifted the BEAM-201 clinical hold and what additional data or manufacturing changes were required.
- The operational status, cost and ramp-up of the North Carolina manufacturing facility.
- The company’s cash burn excluding the $300.0 million Pfizer receivable collection and the timing and terms of future capital raises.
- Progress and economics of the Pfizer, Apellis, Orbital and Verve collaborations, including opt-in decisions, milestones and royalties.
- Resolution and potential exposure related to the research-institution dispute and ongoing CRISPR patent interference proceedings.